| Date | Title | Description |
| 05.02.2025 | SailPoint's IPO: A Second Chance at the Public Market | SailPoint Technologies Inc. is making waves again. The identity security company is gearing up for its second initial public offering (IPO), aiming to raise $1.05 billion. This move comes after a rollercoaster ride through the public and pr... |
| 02.02.2025 | 3 Niche Healthcare Stocks Tackling Rare Diseases The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technolog... | The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technologies. Hence, investors might consider investing in niche healthcare stocks, Immunocore Hol... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 25.06.2024 | Santhera Pharmaceuticals Secures Significant Financing for Growth and Debt Repayment | Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, has recently announced the successful securing of up to CHF 69 million in financing to drive growth, repay debt, and extend its cash runway through to the first half of 202... |
| 24.06.2024 | Santhera secures up to CHF 69 million to fund operations to break-even |
Santhera’s AGAMREE for the treatment of DMD (Duchenne muscular dystrophy) as an alternative to standard corticosteroids is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), an... |
| 17.04.2024 | Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio | PPMD Together: Cincinnati Marks Three Decades of PPMD's Impact and Mayor's Proclamation
Honors Founding President & CEO Pat Furlong's Dedication to the Duchenne Community
CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscula... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States | AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 ... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States | - |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten | AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 2 Jahren erhältlich Dies folgt auf die erste kommerzielle Einführung von AGAMREE in Deutschland im Januar ... |
| 13.03.2024 | Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) | - |
| 05.03.2024 | Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference | - |
| 07.02.2023 | Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance | 2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth
Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA®, Representing YoY Growth of 75% - 80%
2023 FIRDAPSE® Net Revenues Estimated ... |
| 26.12.2022 | 🚀 В эти компании надо инвестировать потому, что их ждёт взрывной рост | Не смотря на рецессию и продолжающийся мировой энергетический кризис эти 4 компании ожидает взрывной рост выручки в 2023 и 2024 годах.
0 Обсудить
25 просмотров
1 Catalyst Pharmaceuticals (Тикер: CPRX) — это коммерческая биофармацевтическая ... |
| 09.08.2022 | Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update | Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase
Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt
Completed Acquisition of Ruzurgi® U.S. and Mexico Commer... |
| 27.10.2021 | 2020 Annual Report | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[Mark One]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2020
OR
TRANSITION REPO... |
| 06.07.2021 | Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer | CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializin... |
| 30.10.2019 | Catalyst Pharma's Firdapse bet on congenital myasthenic syndromes turns sour | Months after Firdapse maker Catalyst Pharmaceuticals filed a lawsuit against the FDA, the Florida company on Wednesday said the drug had failed a pivotal trial in patients afflicted with congenital myasthenic syndrom... |
| 23.09.2019 | Catalyst stock dives, although the fledgling drug maker has no idea why | For the second time in two weeks, Catalyst Pharmaceuticals stock dived substantially, although the drug maker was at a loss to explain the latest drop.
Shares were down as much as 18% on Monday on six times the normal trading volume, prompt... |
| 11.06.2019 | With a substantial discount to Catalyst's Firdapse, is Jacobus poised to win physician, payer support for off-label adult LEMS use? | Weeks ago, the FDA endorsed a Lambert-Eaton myasthenic syndrome (LEMS) drug from family-run New Jersey-based company called Jacobus Pharmaceuticals in pediatric patients, on the basis of adult data, to the surprise of Ca... |
| 21.02.2019 | Catalyst fails to mollify an angry Bernie Sanders over the price of its rare disease drug | After being publicly skewered by Sen. Bernie Sanders (I-Vt.) over the $375,000 price tag for its rare disease drug, Catalyst Pharmaceuticals released a lengthy response defending the steps being taken to ensure the medicine is accessible to... |
| 29.11.2018 | Catalyst Pharma's LEMS drug Firdapse wins FDA nod, as regulators keep the approval engine running at record speed | Turns out, a web error by a company contractor that tipped off investors Catalyst Pharmaceuticals’ $CPRX Firdapse had won approval earlier in the week offered alert traders a quick score. The formal notice that the FDA gr... |
| 17.02.2016 | Catalyst Pharmaceuticals hits FDA snag for Shkreli-esque drug | The drug in question treats a disease called Lambert-Eaton Myasthenic Syndrome, or LEMS. It’s been given away by a New Jersey drugmaker called Jacobus Pharmaceutical Company. But in recent years, Catalyst has jumped on the LEMS bandwagon an... |
| - | Catalyst Pharmaceuticals hits FDA snag for Shkreli-esque drug | Catalyst Pharmaceutical, that ardent admirer of Turing Pharmaceuticals’ M.O., was dealt a bit of a regulatory blow this week. That is, the FDA just sent a “refusal to file” letter to the Florida company for its late-stage drug that’s alread... |
